Gold+
Title: New advances in LA/mUC treatment strategies
- Unmet needs and current treatments in LA/mUC
- Novel treatment strategies for LA/mUC
- “ Current treatment paradigm and medical unmet needs for metastatic urothelial cancer, and, in particular, suggesting new medicine and new treatment strategies being developed for metastatic urothelial cancer after the 2nd line therapy.”
| Address | 521, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea | ||
|---|---|---|---|
| Telephone | 82-2-3448-0504 | Fax | None |
| Website | https://www.astellas.com/kr/ | hoyoon.jung@astellas.com | |
Astellas is a global company with a core business in prescription drugs. "Astellas" is derived from the Greek word "aster," the Latin word "stella," and the English word "stellar," all meaning "star," and the name carries a meaning akin to "aspired stars" or "advanced stars." "Astellas" also draws on a Japanese phrase that translates as "illuminate tomorrow." This phrase expresses our commitment to develop as an R&D-oriented company focused on providing a healthier tomorrow for all through cutting-edge pharmaceuticals.
XTANDI is a prescription medicine used to treat men with prostate cancer that no longer responds to a hormone therapy or surgical treatment to lower testosterone OR has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone. It is not known if XTANDI is safe and effective in females or children.
